These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 17111204)

  • 1. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis.
    Wang X; Smith PL; Hsu MY; Tamasi JA; Bird E; Schumacher WA
    J Thromb Thrombolysis; 2007 Feb; 23(1):41-9. PubMed ID: 17111204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor.
    Wang X; Smith PL; Hsu MY; Ogletree ML; Schumacher WA
    J Thromb Haemost; 2006 Feb; 4(2):403-10. PubMed ID: 16420573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life.
    Nagashima M; Yin ZF; Zhao L; White K; Zhu Y; Lasky N; Halks-Miller M; Broze GJ; Fay WP; Morser J
    J Clin Invest; 2002 Jan; 109(1):101-10. PubMed ID: 11781355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice.
    Wang X; Smith PL; Hsu MY; Gailani D; Schumacher WA; Ogletree ML; Seiffert DA
    J Thromb Haemost; 2006 Sep; 4(9):1982-8. PubMed ID: 16961605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
    Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
    Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
    Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
    Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficient mice.
    Nagashima M; Yin ZF; Broze GJ; Morser J
    Front Biosci; 2002 Feb; 7():d556-68. PubMed ID: 11815293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
    Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
    J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
    Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
    J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activated TAFI Promotes the Development of Chronic Thromboembolic Pulmonary Hypertension: A Possible Novel Therapeutic Target.
    Satoh T; Satoh K; Yaoita N; Kikuchi N; Omura J; Kurosawa R; Numano K; Al-Mamun E; Siddique MA; Sunamura S; Nogi M; Suzuki K; Miyata S; Morser J; Shimokawa H
    Circ Res; 2017 Apr; 120(8):1246-1262. PubMed ID: 28289017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
    Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
    Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
    Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-activatable fibrinolysis inhibitor and sex modulate thrombus stability and pulmonary embolism burden in a murine model.
    Chessum JE; Shaya SA; Rajab D; Aftabjahani A; Zhou J; Weitz JI; Gross PL; Kim PY
    J Thromb Haemost; 2024 Jan; 22(1):263-270. PubMed ID: 37751849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What has been learnt from the thrombin-activatable fibrinolysis inhibitor-deficient mouse?
    Morser J; Gabazza EC; Myles T; Leung LL
    J Thromb Haemost; 2010 May; 8(5):868-76. PubMed ID: 20128866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
    Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
    J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipopolysaccharide augments venous and arterial thrombosis in the mouse.
    Wang X
    Thromb Res; 2008; 123(2):355-60. PubMed ID: 18448153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles.
    Hashimoto M; Yamashita T; Oiwa K; Watanabe S; Giddings JC; Yamamoto J
    Thromb Haemost; 2002 Jan; 87(1):110-3. PubMed ID: 11848438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).
    Grosso G; Vikerfors A; Woodhams B; Adam M; Bremme K; Holmström M; Ågren A; Eelde A; Bruzelius M; Svenungsson E; Antovic A
    Thromb Res; 2017 Oct; 158():168-173. PubMed ID: 28669410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).
    Guimarães AH; Barrett-Bergshoeff MM; Criscuoli M; Evangelista S; Rijken DC
    Thromb Haemost; 2006 Sep; 96(3):325-30. PubMed ID: 16953274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.